Harmony Biosciences
在场
是其中之一......
Harmony Biosciences 是一家在股票代码 HRMY (US) 下上市的公司。
涉及Harmony Biosciences的并购和融资。
- Harmony Biosciences has announced the acquisition of Zynerba Pharmaceuticals (公布2023八月15号).
高管
查看带有其 38 名主要高管的组织结构图
Harmony Biosciences 搜索最多的简介
- Jeffrey Dayno, President and Chief Executive Officer
- Jeffrey Aronin, Non-Executive Chairman
- Mark Graf, Director
高管在Harmony Biosciences变化
- Peter Anastasiou已作为Director加入公司 (新闻发布的2023十一月9号).
- Sandip Kapadia 曾任 Chief Financial Officer, 现升职为 Chief Financial Officer and Chief Administrative Officer (新闻发布的2023十月6号).
创建提醒
跟踪 Harmony Biosciences 的高管变动
生物技术
Harmony Biosciences 拥有 2,297 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Grey Wolf Therapeutics 刚刚宣布为 50 筹款数百万美元。 (公布2024五月25号).
- AbbVie 已收购 Landos Biopharma (公布2024五月25号).
- AltruBio 刚刚宣布为 225 筹款数百万美元。 (公布2024五月24号).
生物技术 行业的其他推荐联系人
消息
Harmony Biosciences 的最新新闻稿
- HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME | Harmony Biosciences
- HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST | Harmony Biosciences
- HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 | Harmony Biosciences
- HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE | Harmony Biosciences
- HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES | Harmony Biosciences
- Harmony Biosciences Certified as a Great Place to Work® for Sixth Consecutive Year, Underscoring Ongoing Commitment to Employee Satisfaction and Growth | Harmony Biosciences
- HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME | Harmony Biosciences
- HARMONY BIOSCIENCES EXPANDS COMMITMENT TO THE RARE NEUROLOGICAL DISEASE COMMUNITY WITH CALL FOR PROGRESS AT THE HEART AND PATIENTS AT THE HEART APPLICATIONS | Harmony Biosciences
- U.S. FOOD AND DRUG ADMINISTRATION GRANTS PRIORITY REVIEW TO HARMONY BIOSCIENCES' APPLICATION FOR WAKIX® (PITOLISANT) IN PEDIATRIC NARCOLEPSY | Harmony Biosciences
- Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Harmony Biosciences
- View more press releases Close
通过电子邮件
